Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer

Stopped early · Phase 2

Conditions studied: Prostatic Neoplasms

In brief

This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.

Key facts

Study ID

NCT00040170

Run by

Transgene

People needed

50

Starts

2002-05-01

Last updated by the study team

2006-11-02

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Rising PSA after surgery or radiation for prostate cancer

You may not qualify if…

• Metastasis or local disease
• Prior hormone treatment

Where it is running

• Arizona Cancer Center — Tucson, Arizona, United States
• UCLA — Los Angeles, California, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.